Wave Life Sciences Ltd. (WVE) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Wave Life Sciences (WVE) Q2 2026: R&D Spend Climbs 18% as Obesity and RNA Editing Pipeline Expands
July 30, 2026
-
Wave Life Sciences (WVE) Q1 2026: Cash Position Extends Runway Into 2028 as RNA Platform Advances
April 28, 2026
-
Wave Life Sciences (WVE) Q4 2025: R&D Spend Rises 15% as Obesity and RNA Editing Pipeline Accelerates
February 26, 2026
-
Wave Life Sciences (WVE) Q3 2025: Inhibin E Knockdown Reaches 85%, Unlocking Durable Obesity Data Path
November 10, 2025
-
Wavelife Sciences (WVE) Q2 2025: Obesity Cohort Expansion to 32 Signals Accelerated Pipeline Ambition
July 30, 2025
-
Wave Life Sciences (WVE) Q1 2025: R&D Spend Climbs 22% as Obesity and AATD Programs Near Data Inflection
July 07, 2025